Abstract
Metabolic syndrome, a “cluster” of metabolic disorders including hypertension, increases the cardiovascular risk, and insulin resistance plays a key role in its pathogenesis. In this syndrome antihypertensive treatment with betablockers is underused because of their adverse metabolic effects. The aim was to review the evidences supporting the reasons for under-using beta-blockers in hypertensive patients with metabolic syndrome. A review of Literature has been carried out via PubMed from 1998 to 2008: most of beta-blockers have adverse effects on insulin sensitivity, carbohydrate and lipid metabolism, and are not recommended in metabolic syndrome. However, some recent large studies have shown a better metabolic profile with newer third generation vasodilating beta-blockers, such as Carvedilol and Nebivolol. Vasodilating action of Carvedilol and Nebivolol, due respectively to alpha1-blocking effect and release of nitric oxide, explains the lack of adverse metabolic effects of these beta-blockers that could also be used in hypertensive patients with metabolic syndrome.
Keywords: Antihypertensive, Beta-blockers, Metabolic syndrome
Current Diabetes Reviews
Title: Antihypertensive Treatment with Beta-Blockers in the Metabolic Syndrome: A Review
Volume: 6 Issue: 4
Author(s): Angelo M. Carella, Giuseppe Antonucci, Matteo Conte, Michele Di Pumpo, Armando Giancola and Elisabetta Antonucci
Affiliation:
Keywords: Antihypertensive, Beta-blockers, Metabolic syndrome
Abstract: Metabolic syndrome, a “cluster” of metabolic disorders including hypertension, increases the cardiovascular risk, and insulin resistance plays a key role in its pathogenesis. In this syndrome antihypertensive treatment with betablockers is underused because of their adverse metabolic effects. The aim was to review the evidences supporting the reasons for under-using beta-blockers in hypertensive patients with metabolic syndrome. A review of Literature has been carried out via PubMed from 1998 to 2008: most of beta-blockers have adverse effects on insulin sensitivity, carbohydrate and lipid metabolism, and are not recommended in metabolic syndrome. However, some recent large studies have shown a better metabolic profile with newer third generation vasodilating beta-blockers, such as Carvedilol and Nebivolol. Vasodilating action of Carvedilol and Nebivolol, due respectively to alpha1-blocking effect and release of nitric oxide, explains the lack of adverse metabolic effects of these beta-blockers that could also be used in hypertensive patients with metabolic syndrome.
Export Options
About this article
Cite this article as:
M. Carella Angelo, Antonucci Giuseppe, Conte Matteo, Di Pumpo Michele, Giancola Armando and Antonucci Elisabetta, Antihypertensive Treatment with Beta-Blockers in the Metabolic Syndrome: A Review, Current Diabetes Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339910791658844
DOI https://dx.doi.org/10.2174/157339910791658844 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Clinical Audit on Adherence to the Guidelines Directed Medical Therapy in Patients Admitted with Heart Failure
Current Drug Safety Editorial [Hot Topic: Benefits, Problems and Alternatives to COX-2 Inhibition (Guest Editor: Angel Lanas)]
Current Topics in Medicinal Chemistry Teenage-pregnancies from a Human Life History Viewpoint – an Updated Review with Special Respect to Prevention Strategies
Current Women`s Health Reviews Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Perivascular Inflammation and Hypertensive Cardiovascular Remodeling
Current Hypertension Reviews A Novel Design of Combining the Angiotensin Converting Enzyme (ACE) Inhibitor Captopril with the Angiotensin Receptor Blocker (ARB) Losartan Using Homo Coupling via PEG Diacid Linker
Recent Patents on Cardiovascular Drug Discovery Growth Factor Therapy in Atherosclerotic Disease-Friend or Foe
Current Pharmaceutical Design Overview of Murine Atherosclerosis Series
Current Drug Targets Value of Sodium-Glucose Co-Transporter 2 Inhibitor Versus Traditional Medication in Microalbuminuric Diabetic Patients
Current Diabetes Reviews A Therapeutic Target for Microvascular Complications in Diabetes: Endothelium- Derived Hyperpolarizing Factor
Current Cardiology Reviews subject Index To Volume 1
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Biomedical Advances for Spaceflight Improve Healthcare on Earth
Current Biotechnology Atorvastatin and Diabetic Vascular Complications
Current Pharmaceutical Design Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma
Current Drug Delivery Pulmonary Vascular Function in Insulin Resistance and Diabetes
Current Vascular Pharmacology Preface [Hot topic: Anti-Hypertensive Agents in Relation to Modifying Coronary Risk Factors (Executive Editor : Aurelio Leone)]
Current Pharmaceutical Design High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Pre-CKD- Do we Need Another Hero?
Current Vascular Pharmacology